uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
uniQure (NASDAQ: QURE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
uniQure (NASDAQ: QURE) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $10.00 to $9.00. They now have a "neutral" rating on the stock.
uniQure (NASDAQ: QURE) had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $14.00. They now have an "outperform" rating on the stock.
uniQure (NASDAQ: QURE) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.